ALK B ALK-ABELLO A/S

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions by managerial staff:

The Board of Directors has previously granted share options and performance shares in ALK-Abelló A/S, re. company release no. 5/2020 of 19 March 2020. The right to share options and performance shares may be achieved in March 2023, provided that ALK achieves the pre-agreed targets for vesting and that the employment relationship with the ALK Group has not been terminated by the Company on objective grounds or terminated.

The final calculations have now been completed, and final allocation of share options and delivery of performance shares have taken place as stated in the attached pdf-file.

ALK-Abelló A/S



For further information please contact:

Investor Relations: Per Plotnikof, tel. , mobile

Media: Maiken Riise Andersen, tel.

Attachment



EN
02/03/2023

Underlying

ALK BALK-ABELLO A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ALK-ABELLO A/S

 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Storaktionærmeddelelse

Storaktionærmeddelelse I henhold til § 30 i Lov om kapitalmarkeder skal ALK (ALKB:DC / OMX: ALK B) hermed oplyse, at Arbejdsmarkedets Tillægspension (“ATP”) har meddelt, at ATP har reduceret sin ejerandel i ALK til under 5% af aktiekapitalen (tidligere 5,0%). Meddelelsen fra ATP er vedhæftet denne selskabsmeddelelse. ALK-Abelló A/S For yderligere oplysninger kontakt venligst:Investor Relations: Per Plotnikof, tlf. 4574 7527, mobil 2261 2525Presse: Maiken Riise Andersen, tlf. 5054 1434 Om ALKALK er en global, specialiseret medicinalvirksomhed med fokus på allergi og allergisk astma. Virks...

December 19, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

Major shareholder announcement

Major shareholder announcement Pursuant to Section 30 of the Danish Capital Markets Act, ALK (ALKB:DC / OMX: ALK B) hereby announces that Arbejdsmarkedets Tillægspension (“ATP”) (The Danish Supplementary Labour Market Pension) has informed ALK that ATP has reduced its ownership in ALK to below 5% of the share capital (previously 5.0%). The notification (in Danish) from ATP is attached to this company release. ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. , mobile Media: Maiken Riise Andersen, tel. About ALKALK is a global specialty ...

December 19, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK udnævner Edward Jordan til ny direktør for de kommercielle aktivit...

ALK udnævner Edward Jordan til ny direktør for de kommercielle aktiviteter i Nordamerika ALK (ALKB:DC / OMX: ALK B) har i dag annonceret udnævnelsen af Edward Jordan til ny Executive Vice President (EVP) og direktør for de kommercielle aktiviteter i Nordamerika med virkning fra 5. januar 2026. Edward Jordan afløser Søren Niegel, som midlertidigt har varetaget rollen i forlængelse af beslutningen, gældende fra 1. oktober 2025, om at inkludere ALK's to centrale kommercielle regioner, Europa og Nordamerika, i selskabets topledelse (Executive Leadership Team, ELT) for yderligere at styrke eksek...

December 1, 2025 1 EN
 PRESS RELEASE
Free
ALK B ALK-ABELLO A/S

ALK appoints Edward Jordan as new EVP and head of Commercial Operation...

ALK appoints Edward Jordan as new EVP and head of Commercial Operations North America ALK (ALKB:DC / OMX: ALK B) today announced the appointment of Edward Jordan as new Executive Vice President (EVP) and head of Commercial Operations in North America as per 5 January 2026. Edward Jordan succeeds Søren Niegel who has temporarily assumed the position following the decision, effective 1 October 2025, to elevate ALK’s two key commercial regions, Europe and North America. into the Executive Leadership Team (ELT) to further strengthen the execution of ALK’s Allergy+ strategy. Edward Jordan, an A...

December 1, 2025 1 EN
ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
11/14/25 November 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch